Global Conjugate Vaccines Market 2020-2024 | Evolving Opportunities with Aurobindo Pharma Ltd. and GlaxoSmithKline Plc | Technavio

Technavio has announced its latest market research report titled global conjugate vaccines market 2020-2024 (Graphic: Business Wire)

LONDON--()--Technavio has been monitoring the global conjugate vaccines market and the market is poised to grow by USD 7.27 billion during 2020-2024 at a CAGR of over 9% during the forecast period. Request Free Sample Pages

Read the 151-page research report with TOC on "Conjugate Vaccines Market Analysis Report by Geography (Asia, Europe, North America, and ROW), by Type (Multivalent conjugate vaccine and Monovalent conjugate vaccine), and Segment Forecasts, 2020-2024".

https://www.technavio.com/report/conjugate-vaccines-market-industry-analysis

The increasing awareness about immunization programs and access to vaccines and emergence of strategies to improve conjugate vaccine manufacturing is anticipated to boost the growth of the market.

Initiatives aimed at increasing the awareness about well recognized and successful public health immunization programs are promoting the overall vaccine coverage around the globe. For instance, World Pneumonia Day is celebrated every year on November 12 to lower the incidence of pneumonia and reduce the resultant mortality rate. Similarly, other programs are focusing on improving drug delivery and diagnostics to address the health issues in low and middle-income countries. Such initiatives targeted towards boosting the access to vaccines will drive the demand for conjugate vaccines. Conjugate vaccines are developed to immunize against a single antigen or two or more strains of the same microorganism. Thus, the promotion of immunization programs will lead to an increase in demand for conjugate vaccines leading to market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Conjugate Vaccines Market Companies:

Aurobindo Pharma Ltd.

Aurobindo Pharma Ltd. is headquartered in India and operates the business under the segment: Pharmaceuticals. The company offers a conjugate vaccine, Pneumococcal conjugate vaccine. This vaccine is developed to protect infants, young children, and adults against disease caused by the bacterium Streptococcus pneumoniae.

GlaxoSmithKline Plc

GlaxoSmithKline Plc is headquartered in the UK and offers products through the following business units: Pharmaceuticals, Vaccines, and Consumer healthcare. The company offers MENVEO vaccine to prevent the risk of developing invasive meningococcal disease.

Integrated Biotherapeutics Inc.

Integrated Biotherapeutics Inc. is headquartered in the US and operates under the business segment: Biopharmaceuticals. The company offers IBT-V02 vaccine for the prevention of recurrent skin and skin structure infections.

Merck & Co. Inc.

Merck & Co. Inc. is headquartered in the US and offers products through the following business segments: Pharmaceuticals and Animal health. The company offers PedvaxHIB, a haemophilus b conjugate vaccine.

Mitsubishi Tanabe Pharma Corp.

Mitsubishi Tanabe Pharma Corp. is headquartered in Japan and offers products through the business segment: Pharmaceuticals. The company offers a hemophilus b conjugate vaccine, HibTITER, to prevent infections that can be caused by Hemophilus influenza type b bacteria.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Conjugate Vaccines Type Outlook (Revenue, USD Million, 2020-2024)

  • Multivalent conjugate vaccine
  • Monovalent conjugate vaccine

Conjugate Vaccines Regional Outlook (Revenue, USD Million, 2020-2024)

  • Asia
  • Europe
  • North America
  • ROW

Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Health Care include:

Pediatric Vaccine Market – Global Pediatric Vaccine Market by product (conjugate vaccines and others, live-attenuated vaccines, toxoid vaccines, and inactivated vaccines).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: https://www.technavio.com

Release Summary

Global conjugate vaccines market is poised to grow by USD 7.27 billion during 2020-2024 at a CAGR of over 9% during the forecast period.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: https://www.technavio.com